Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2015

View Archived Issues

Phase I study shows promising results for GS-5745 in patients with advanced solid tumors

MEDI-0639 shows preliminary evidence of antitumor activity

IDRI studies ID-93 + GLA-SE vaccine following completion of TB treatment

Circadian Technologies begins phase I study of OPT-302 in wet AMD

CEA-targeted cytokine targets tumoral cells and shows immmune activity in tumor site

Chimerix patents antiviral agents

NIH grant supports GeoVax's clade C HIV vaccine development program

Nanobiotix starts phase I/II trial of NBTXR-3 in liver metastasis and hepatocellular cancer

TES Pharma and Ecole Polytechnique Federale de Lausanne collaborate on kynurenine pathway modulators

LG Life Sciences discloses a novel GPR120 agonist

First patient dosed in seliciclib trial in Cushing's disease

Taisho divulges OX-1 and -2 antagonists

Lycera introduces F1F0-ATPase inhibitors

New study shows promising activity of LSD1 inhibitor RN-1 for sickle cell disease

ESN-364, an optimized NK3 receptor antagonist for sex-hormone disorders

Biogen and AGTC collaborate to develop gene-based therapies for ophthalmic diseases

Antitumor agent Farydak approved in Japan

FDA accepts IND for MAGE-A10 T for NSCLC

Innate Pharma and IPC collaborate on translational research for immune checkpoint inhibitors

Xiaflex approved in Japan for Dupuytren's contracture

Acoalan approved in Japan

McGill University patents anti-GD cancer vaccine

Dicerna Pharmaceuticals develops DsiRNAs targeting TTR for amyloidosis

S. aureus vaccine in early development at Evaxion Biotech

Federal grants support research at University of Pittsburgh on mosquito-borne viruses

Targovax confirms closing of the acquisition of Oncos Therapeutics